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An important underlying principle in radiation oncology is to enhance tumour control 
by delivering the highest dose to the tumour whilst minimizing toxicity to the 
surrounding normal tissues. This optimisation of the therapeutic ratio remains an 
ongoing challenge for radiation oncologists in their search for the optimal treatment 
modality. However, major technological advances have improved the delivery of 
external beam radiation therapy (EBRT). For example, the integration of computed 
tomography (CT) imaging and computer-assisted dose calculation algorithms have 
resulted in three-dimensional (3D) image-based treatment planning and delivery. 
Intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy 
(VMAT) represent a further important advancement, as these provide the opportunity 
to sculpt the dose distribution to almost any complex-shaped target volume, whilst 
sparing adjacent normal structures (1). 
Although EBRT has experienced dramatic technological innovations, similar 
developments in brachytherapy have not been attained. Historically, brachytherapy 
was among the first established and successful techniques for conformal cancer 
treatment as it delivers a high tumour dose with a rapid dose fall off, leading to sparing 
of normal tissues. For these reasons, it has remained a fundamental treatment 
component in radiation oncology since the early twentieth century. Traditionally, 
brachytherapy planning and treatment has been based on orthogonal radiography. 
Although dose distribution was calculated in three dimensions it could not be viewed 
in 3D relative to the patient anatomy. In recent years, brachytherapy practice has 
adopted the exciting technological concepts of 3D image-guided EBRT. Development 
in cross-sectional imaging with CT, magnetic resonance imaging (MRI) and real-time 
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ultrasound-guided techniques, coupled with sophisticated dosimetric planning systems, 
have enabled the accurate and reliable delivery of highly conformal radiotherapy using 
brachytherapy (2). 
There is strong interest to integrate 3D image-based brachytherapy into the 
management of several cancer sites, including prostate cancer and cervix cancer. The 
use of brachytherapy for prostate cancer allows the delivery of hypofractionated 
radiation therapy, thereby conferring a therapeutic radiobiological advantage (3). High-
dose rate (HDR) afterloading systems allow greater flexibility of source loading 
patterns and dose delivery that makes it an attractive technology for dose escalation. 
Low-dose rate (LDR) permanent seed brachytherapy for early stage prostate cancer is 
another technology that has become increasingly popular due to the ability to place 
seeds accurately under real-time transrectal ultrasound guidance (4, 5). Such 
techniques have advantages for both the patient and treatment centre due to the 
significant decrease in treatment time, improving patient convenience and treatment 
accessibility, respectively (6). For cervix cancer, image-guided brachytherapy 
combines greater accuracy in tumour volume definition with reduced dose to the 
adjacent organs at risk.  
However, the implementation of new and innovative technologies relies upon careful 
and thorough analysis of both the effectiveness and safety of the treatment. Whilst 
randomised controlled trials are the most rigorous form of analysis, the performance of 
such trials is not always possible for both practical and scientific reasons. Additionally, 
whilst multi-institutional collaboration is desirable, this may not be achievable due to 
the conflicting areas of interest and expertise in radiation oncology departments. It is 
therefore imperative that careful evaluation of innovative technologies, such as those 
employed in modern brachytherapy, are undertaken by those centres wishing to 
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implement or enhance their brachytherapy program. Analysing the benefits and 
potential detriments of image-guided brachytherapy is fundamental to understanding 
its role in future radiation oncology paradigms, as well as the potential impact on the 
workload of a brachytherapy program. 
Here we summarize our work on the role of image-guided brachytherapy in prostate 
and cervix cancer, with a view to providing recommendations for the implementation 
of a prostate brachytherapy program and to further optimise the delivery of safe and 
effective brachytherapy for cervix cancer. 
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Is there a role for image-guided high-dose rate (HDR) 
brachytherapy to improve the cure rate for patients 




The biological advantage of HDR brachytherapy relates to the ability to deliver higher 
radiation dose per fraction safely and with high conformation to the prostate gland. 
There is evidence that prostate cancer cells respond favourably to radiation delivered at 
large dose per fraction described by a survival curve with a low α/β ratio. The actual 
figure remains unknown, but most investigators suggest it is well below five and 
possibly as low as two or three, with extreme estimates as low as 1.5 Gy (3, 7-10). The 
significance of this is that dose escalation via hypofractionation is biologically 
advantageous due to the comparatively lower sensitivity to fractionation changes of 
surrounding critical organs, such as bladder and rectum (α/β ratio = 3-5 Gy). Thus, 
hypofractionation most likely increases tumour cell killing effect. 
HDR brachytherapy is often used as a boost in conjunction with external beam 
radiation therapy. In general, patients treated with HDR brachytherapy present with 
unfavourable prognostic factors, such as palpable tumour or extracapsular disease, 
higher Gleason score and pre-treatment PSA greater than 10 ng/ml (11). Results from 
two randomized controlled trials (12, 13) and single institutional reports of HDR 
brachytherapy in combination with EBRT confirm HDR brachytherapy as an 
alternative technique for dose-escalation, with tumour control rates similar to those 
obtained with EBRT alone. Estimated 5- and 8-year biochemical free survival ranges 
from 65% to over 90%, dependent on the number of risk factors present (14-17) 
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2. Our results 
 
Dose escalation with 3D conformal external beam radiation therapy (3DCRT) or 
IMRT improves outcome with acceptable toxicity profiles (18, 19). HDR 
brachytherapy in combination with 3DCRT is an alternative method with the ability to 
deliver a highly conformal radiation treatment with a favorable toxicity profile. The 
purpose of our study was to report the outcomes of 196 men treated with HDR 
brachytherapy for dose escalation in combination with 3DCRT, and compare them 




From 1998 to 2003, 587 patients were treated at The William Buckland Radiotherapy 
Centre (Monash University, Melbourne, Australia) for clinically localized prostate 
cancer. Patients received either 3DCRT (median 46 Gy) with a single HDR 
brachytherapy implant (196 patients) delivering a fractionated dose of 18 Gy 
(combined group), or 3DCRT (median 70 Gy, 387 patients, “3DCRT alone”). There 
were 41.9% intermediate-risk and 42.6% with high-risk disease. In all, 441 patients 
(75.1%) received neoadjuvant and 116 patients (19.8%) adjuvant androgen deprivation 
therapy (ADT). The American Society of Therapeutic Radiology and Oncology 









Median follow-up was 5.5 years. The 5-year and 7-year biochemical control (BC) rates 
were 82.5% and 80.3% for the combined group and 81.3% and 71% for 3DCRT alone; 
for overall survival they were 91.9% and 89.5% vs. 88.7% and 86.2% (n.s.); whilst 
cause-specific survival was 96.9% and 96.1% vs. 97.6% and 96.2% (n.s.), respectively. 
Cox proportional hazard regression analysis for BC revealed that low Gleason grade, 
HDR brachytherapy combined with 3DCRT and adjuvant ADT were significant in 
predicting BC. RTOG grade 3 late urinary and rectal morbidity rates were 7.1% and 
0% for HDR brachytherapy in combination with 3DCRT, respectively. No grade ≥ 4 




Similar to other reports including randomized clinical trials, we demonstrated that 
3DCRT combined with HDR prostate brachytherapy resulted in excellent long-term 
biochemical control, overall survival and cause-specific survival (12-14, 16, 17, 21-
24). On multivariable analysis, combined treatment was associated with a statistically 
significant improved biochemical control of 36% (p = 0.047) when compared to 
3DCRT alone, adjusting for adverse risk factors in the combined group. No RTOG 









Image-guided HDR brachytherapy has gained an important role in the management of 
localized prostate cancer. There is a strong dose-response relationship in prostate 
cancer and HDR brachytherapy provides an efficient method to achieve dose 
escalation that is needed for improved cancer control with low toxicity. 
There are a number of reasons to justify the establisment of a HDR prostate 
brachytherapy program. Overall treatment time is shortened using hypofractionation, 
which is more convenient for patients, and the HDR brachytherapy implant 
circumvents organ motion thereby avoiding the need for wide safety margins during 
treatment application. In contrast, delivering dose escalation with conventional EBRT 
fractionation requires a prolonged treatment time of 8 to 9 weeks using correction for 
daily organ motion with image guidance, resulting in more costly and less time 
efficient treatment for the patient and the radiation oncology department (25). The 
treatment optimization process with HDR brachytherapy allows varying dose 
distributions across the target and selective dosing of the peripheral zone or boosting of 
a dominant intraprostatic lesion (26). Additionally, HDR prostate brachytherapy allows 
for greater sparing of rectum and bladder than is achievable with EBRT alone (27, 28). 
The main disadvantages of HDR brachytherapy include the relative invasiveness of the 
procedure and the specialised skill set required (29). 
With a better understanding of this technique combined with the current trend to use 
hypofractionation in the curative treatment of prostate cancer, further improvements in 
cancer control may be possible. Clinical studies comparing image-guided HDR 
brachytherapy using different fractionation schemes in combination with EBRT with 
dose-escalated EBRT alone are in progress (29). Such studies will ensure that all 
relevant factors, including economic perspective, are taken into account when deciding 
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upon the optimal treatment strategy to improve cure rates for patients with prostate 




Figure 4. CT-scan image before 
brachytherapy treatment delivery 
with transperineally inserted 
temporary sealed-tip hollow catheters 
into the prostate gland. Red indicates 
planning target volume (PTV) and 
prostate; light blue, 114% isodose 
line; yellow and green, 95% and 66% 
isodose lines, respectively. 
Urethra=dark blue, Rectum=purple 
 
 
Picture: Courtesy of A/Prof Jeremy L Millar 
The William Buckland Radiotherapy Centre 
Melbourne, Australia 
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Can MRI-guided intracavitary brachytherapy improve 





With evolving clinical experience with image-guidance in radiation oncology, a 
number of institutions have implemented MRI-based brachytherapy treatment for the 
curative management of cervical cancer. Tumour extension is imaged at the time of 
diagnosis and at the time of brachytherapy in order to individualize target volumes, 
thereby taking into account the tumour response over time. At the same time, the dose 
to organs at risk is adapted in relation to the applicator in 3D. Thus, with the assistance 
of image-guidance, dose escalation to the target volumes is achieved to ensure 
improved local control (30, 31). 
The use of MRI in the staging process of cervical cancer, complementary to the 
clinical International Federation of Gynaecology and Obstetrics (FIGO) criteria, is well 
established (32, 33) and has become the investigation of choice to assess tumour 
extension prior to any treatment decision. For brachytherapy, the important role of 
MRI is afforded by the superior contrast resolution and image quality of soft tissues in 
the pelvis compared with ultrasound or CT (34, 35). Importantly, MRI enables the 
visualisation of cervical tumour size and volume, distinction of tumour from normal 
uterus or cervix and extension of disease into parametrial or vaginal tissues (36). T1- 
and T2-weighted axial, coronal and sagittal MRI scans with contrast using a pelvis 
surface coil are the preferred sequences (37). In particular, T2-weighted images of the 
cervical tumour display an increased signal intensity compared to normal cervical 
stroma, whereas paracervical soft tissues show high signal intensity on T1- and T2-
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weighted images (38). It has been demonstrated that the use of MRI compared to CT 
provides information for more precise topographic definition and delineation of tumour 
extension and equal precision for organs at risk in relation to the applicator, and is thus 
integral to brachytherapy planning (35, 39, 40). 
 
2. Our results 
 
The purpose of our study was to report on the benefits of 20 patients whose treatment 
has been optimized with 3D MRI image-guided intracavitary brachytherapy, and 




A total of 20 patients with International Federation of Gynaecology and Obstetrics 
(FIGO) stage IB-IV cervix cancer had an MRI-compatible intrauterine BT applicator 
inserted after external beam radiotherapy (EBRT). MRI scans were acquired, and the 
gross tumour volume at diagnosis (GTVD) and at BT (GTVB), the high (HR) and 
intermediate risk (IR) clinical target volume (CTV), and the rectal, sigmoid and 
bladder walls were delineated according to the recommendations of the Groupe 
Européen de Curiethérapie – European Society for Therapeutic Radiology and 
Oncology (GEC-ESTRO) Working Group (Figure 1) (42, 43). Pulsed-dose-rate BT 
was planned and delivered in a conventional manner. Optimized MRI-based plans 
were developed and compared to the conventional plans. 
 







The HR CTV and intermediate-risk CTV were adequately treated (the percentage of 
volume treated to ≥ 100% of the intended dose was > 95%) in 70% and 85% of 
patients with the conventional plans, respectively, and in 75% and 95% of the patients 
with the optimized plans, respectively. The minimal doses to the contiguous 2 cm3 of 
the rectal, sigmoid and bladder wall were 16±6.2, 25±8.7 and 31±9.2 Gy, respectively. 
With MRI-guided BT optimization, it was possible to maintain coverage of the HR 
CTV and reduce the dose to normal tissues, especially in patients with small tumours 
at the time of BT (p < 0.05). In these patients, the HR percentage of volume treated to 
≥ 100% of the intended dose approached 100% in all cases, and the minimal dose to 
the contiguous 2cm3 of the rectum, sigmoid and bladder was 12-32% less than with 




The significant reduction in the contiguous 2 cm3 doses to rectum, sigmoid and bladder 
has the potential to substantially reduce morbidity, given that current treatment 
Figure 1. Schematic diagram 
for cervix cancer, limited 
disease, with gross tumour 
volume (GTV), intermediate 
risk (IR) clinical target 
volume (CTV) and high risk 
(HR) CTV for definitive 
treatment; coronal and 
transversal view) (42, 43) 
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approaches have escalated the dose to the point at which even small incremental 
changes can translate into large clinical effects (44). This is in contrast to patients with 
large residual tumours at the time of brachytherapy, for whom the objective of 
adequate target coverage might preclude significant sparing of organs at risk. Among 
our patients with large target volumes, no difference was found between the optimized 
and conventional sigmoid and bladder D2cm3 values, and the optimized rectal D2cm3 
increased by 14%. As a consequence, patients with large residual tumour bulk after 
external beam radiation therapy are probably not optimally treated with intracavitary 
brachytherapy alone, and instead should be considered for either a combination of 
intracavitary and interstitial brachytherapy (31, 45) or an IMRT boost (46). Our group 




Brachytherapy is integral to the successful management of cervix cancer, and in 
particular, intracavitary treatment permits delivery of a high dose of radiation to the 
cervix and paracervical tissues while minimizing dose to the bladder and bowel. 
Advances in imaging and computer dosimetry have been implemented into 
gynaecologic brachytherapy (2). However, it is necessary to evaluate the clinical 
benefit and associated costs of this complex system of MRI-based 3D treatment 
planning and performance of gynaecologic brachytherapy, as presented by our group. 
These include access to an MRI scanning device, MRI compatible applicators, digital 
network with integration of a 3D imaging device and interface for data transfer, 3D 
treatment planning system, trained personnel (physicians, physicists, radiotherapy 
technicians, nurses) and a multidisciplinary team approach. Potter et al. estimated the 
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additional costs necessary for setting up a MRI-based gynaecologic brachytherapy to 
be 10-15% higher of the normal costs of conventional brachytherapy (44). In addition, 
several patient and technical factors remain to be addressed in relation to the 
integration of MRI-based brachytherapy into routine clinical practice. This includes the 
identification of the appropriate patient population, the challenges of real-time 
contouring and plan optimization, the refinement of normal tissue constraints, 
improved understanding of the biology underlying tumour regression in relation to 
target dose optimization, and geometric and dosimetric stability during applicator 
insertion. This should be performed in a multicentre setting, using a combined 
intracavitary and interstitial approach, as well as state of the art external beam radiation 
therapy. The large, international, multicenter European Study on MRI-guided 
brachytherapy in locally advanced cervical cancer (EMBRACE) 
(www.clinicaltrials.org, www.embracestudy.dk) will be instrumental in addressing 
these issues and advancing the use of brachytherapy in this disease (31). If this proves 
to be feasible, there is large potential to increase disease control and overall survival in 
patients with locally advanced cervical cancer in the near future. 





Modern brachytherapy has made significant progress and obstacles towards image-
guided brachytherapy for prostate and cervix cancer have been overcome. Numerous 
reports including our results showed that with the support of image guidance high-dose 
conformal radiotherapy is being delivered through modern brachytherapy techniques 
(2). Given their ability to deliver highly conformal dose distributions, it is not 
surprising that modern brachytherapy has been suggested as an alternative for 
sophisticated EBRT techniques including IMRT. Thus, radiation oncologists are facing 
the challenge that there are many advanced radiotherapy solutions from whitch to 
make a choice. The number of options is even larger when considering all the 
potentially beneficial combinations of radiotherapy modialities or dose fractionation 
schemes in addition to various chemotherapy and surgery solutions. Recently, the use 
of robotic-guided brachytherapy at gynaecological and genitourinary sites has been 
presented (48, 49). This may set another trend the way brachytherapy will be delivered.  
In todays health care environment the treatment decision is not only driven by forces 
improving treatment succes, but also by economy, patient safety, preference and 
convenience. As one in three Europeans will be diagnosed with cancer at some time in 
their lives and the number affected will increase as people live longer (50), these 
questions of how to choose the appropriate treatment are becoming very important. 
However, improving therapeutic outcome means selecting the right combinaiton of 
therapies and to have these available requries timely investment in working 
relationships, skills and technologies. In this complex environment, careful evaluation 
of new technologies, such as those employed in modern brachytherapy, remains key to 
practice best paitent care in the 21st century. 
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